To include your compound in the COVID-19 Resource Center, submit it here.

Arvinas adds to momentum with Bayer deal for protein degraders

Arvinas is building on its recent momentum by signing Bayer as its fourth pharma partner in a deal announced Tuesday that aims to broaden its pipeline of protein degraders into new indications. The partnership comes in a 14-month span that has seen the biotech raise $185 million in a series C and

Read the full 520 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers